<DOC>
	<DOCNO>NCT00620750</DOCNO>
	<brief_summary>Naltrexone opioid antagonist high affinity mu opioid receptor . The efficacy extended-release naltrexone ( Vivitrol ) treatment alcohol dependence demonstrate clinical trial , raise prospect integrate pharmacologic treatment alcohol dependence general medical care setting . However , feasibility implementing United States Food Drug Administration approve treatment front-line setting need demonstrate . This open-label pilot feasibility study implement treatment Vivitrol primary care medical clinic safety net hospital system affiliate urban academic center .</brief_summary>
	<brief_title>Extended-release Naltrexone Alcohol Dependence Primary Care</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Current alcohol dependence Age 18 old English Spanishspeaking Without untreated severe mental illness Liver enzymes ( alanine aminotransferase aspartate aminotransferase ) â‰¤ 3x normal Kept 2 last 3 clinic primary care appointment and/or work telephone number contact directly Either ) currently abstinent ( e.g. , referred inpatient 'detox ' setting ) b ) ability , clinician 's judgment , achieve maintain abstinence If female childbearing potential , must use adequate contraception Able understand study procedure Currently opioid dependent require ongoing treatment opioids indication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Alcohol dependence</keyword>
</DOC>